Fig. 1.
Schematic representation of the treatment schedule used in this patient series.
APO course consisted of doxorubicin 75 mg/m2 days 1 and 22, vincristine 1.2 mg/m2 days 1, 8, and 22, and prednisone 50 mg/m2 days 1 to 22. DHAP course consisted of cisplatin 100 mg/m2 day 1, Ara-C 4 g/m2 day 2, dexamethasone 40 mg days 1 to 4.
